Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS (pwMS) and insufficient IgG responses after the standard immunization scheme. Eight pwMS that were treated with fingolimod received a third homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna’s mRNA-1273 or Pfizer-BioNTech’s BNT162b2 vaccine. We quantified the serum levels of IgG antibodies against the receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered protective. After the third vaccination, we found clinically relevant IgG titers in four out of eight individuals (50%). We conclude that the humoral immune response may reach protective levels after the third preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots in S1PR-modulator treated pwMS ahead of schedule may be a strategy to overcome insufficient humoral immune responses following the standard vaccination scheme.
【저자키워드】 COVID-19, SARS-CoV-2, vaccination, humoral immune response, fingolimod, S1PR-modulator, 【초록키워드】 BNT162b2 vaccine, multiple sclerosis, mRNA vaccine, mRNA-1273, immunization, SARS-CoV-2 vaccine, IgG antibody, mRNA, Antibody titer, receptor, homologous, Protective, IgG titer, dose, IgG response, Serum level, individual, mRNA-based vaccine, clinically, eight, treated, overcome, the receptor-binding domain, quantified, 【제목키워드】 mRNA, response, Multiple, sclerosis,